摘要
为了研究WT1基因在骨髓增生异常综合征 (MDS)和急性白血病 (AL)患者中的表达及其与临床预后的关系 ,采用逆转录 聚合酶链反应 (RT PCR)方法检测 2 2例MDS和 6 9例AL的WT1mRNA的表达。结果表明 ,WT1mRNA在MDS RA及MDS RAS中低表达 ,阳性率为 10 % (1/10 ) ;在MDS RAEB和MDS RAEB t中高表达 ,阳性率为 91.7% (11/12 ) ,两者差异有统计学意义 (P <0 .0 1)。WT1mRNA在各型急性白血病中均有表达 ,初发和复发急性白血病中WT1mRNA的阳性率 (6 9% )高于缓解患者 (12 .5 % ) (P <0 .0 1)。初发与复发AL的WT1mRNA的相对表达量无差异 ,而MDS RAEB和RAEB t的表达量低于初发AL患者。WT1mRNA阳性的AML患者的化疗缓解率 (4 1% )低于阴性患者 (78% ) ;WT1基因相对表达量≥ 1的AML患者的CR率 (18% )低于 <1的患者 (5 5 % )。结论 :WT1基因在MDS RAEB和MDS RAEB t中的表达明显高于MDS RA和MDS RAS ,动态监测WT1基因的表达可能有助于监测MDS的病情变化。WT1基因表达与否及表达高低与初发AL的预后有关 ;WT1基因是急性髓细胞白血病的一个独立的预后因素。
To study the expression and significance of WT1 gene in patients with myelodysplastic syndrome (MDS) and acute leukemia (AL),RT-PCR was applied to monitor WT1 gene expression in 22 patients with MDS and in 69 patients with AL. The results showed that the positive rate of WT1 mRNA in MDS-RA and MDS-RAS was lower than that in MDS-RAEB and MDS-RAEB-t (10% versus 91.7%,P<0.01). WT1 mRNA could be expressed in all subtype of AL,It was detected in 69% of newly diagnosed and relapsed patients,and in 12.5% patients CR. There was no difference at the relative expression level between newly diagnosed AL patients and relapsed patients,while the relative level of WT1 in MDS-RAEB and MDS-RAEB-t was lower than that in newly diagnosed AL. The CR rate in AML patients with positive expression was lower than that in patients with negative expression (41% versus 78%,P≤0.05). AML patients with relative level of WT1 mRNA ≥1 had lower CR rate (18%) than those with relative level <1 (55%). It is concluded that the expression of WT1 gene in patients with MDS-RAEB and RAEB-t was higher than that in patients with RA and RAS. The detection of WT1 gene may be useful for assessing disease progress of patients with MDS. The expression of WT1 gene and its expression level have associated with the prognosis of newly diagnosed patients with AL,that WT1 gene may be an independent prognostic factor in AML.
出处
《中国实验血液学杂志》
CAS
CSCD
2004年第4期464-466,共3页
Journal of Experimental Hematology
基金
浙江省科学技术厅重点资助项目 (编号 2 0 0 3C2 3 0 13 )
